Cancer Clinical Trials at MidMichigan Health

Clinical research studies serve to improve cancer treatment and ensure the highest possible level of patient care. Patients involved in research studies play an important role in advancing evidence-based medicine to future patients. There are tremendous advantages for patients having access to nationally sponsored clinical trials closer to home including treatment options that might otherwise not be available to them and by avoiding treatment delays and decreasing lengthy travel times. Patients are eligible to participate in research studies only after specific eligibility criteria have been met.

Current Cancer Clinical Trials at MidMichigan

Breast Cancer

  • ALLIANCE A011401: (Dr. Le) (BWEL TRIAL): Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer.
    • Currently enrolling participants.
    • NCT: 02750826
  • SWOG 1418:(Dr. Hurtubise): A randomized phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor negative breast cancer with > 1cm residual invasive cancer or positive lymph nodes after neoadjuvant chemotherapy.
    • Currently enrolling participants.
    • NCT: 02954874

Lung Cancer

  • ALLIANCE A151216: (Dr. Regenbogen) (ALCHEMIST Trial): Adjuvant lung cancer enrichment marker identification and sequencing trial.
    • Currently enrolling participants.
    • NCT: 02194738
  • ALLIANCE A081105: (Dr. Regenbogen) (ALCHEMISTTrial): Randomized double blind placebo controlled study of Erlotinib or placebo in patients with completely resected epidermal growth factor mutant non-small cell lung cancer.
    • Currently enrolling participants.
    • NCT: 02193282
  • EA5142: (Dr. Regenbogen) (ALCHEMIST Trial): A randomized phase III study of Nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers.
    • Currently enrolling participants.
    • NCT: 02595944
  • E4512:(Dr. Regenbogen) (ALCHEMIST Trial): A phase III double blind trial for surgically resected early stage non-small cell lung cancer: Crizotinib verses placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein (ALCHEMIST).
    • Currently enrolling participants.
    • NCT: 02201992

Multiple Myeloma

  • E1A11: (Dr. Regenbogen) (ENDURANCE Trial): A randomized phase III trial of Bortezomib, Lenalidomide, and Dexamethasone verses Carfilzomib, Lenalidomide, and Dexamethasone followed by limited or indefinite duration Lenalidomide maintenance in patients with newly diagnosed symptomatic multiple myeloma.
    • Enrollment goals met. Patiens in follow-up only.
    • NCT: 01863550


  • PRN1008-010: (Principia Sponsor- Not NIH) - Open 12/2018 (1 potential 01-2019): An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed ITP
    • Currently enrolling participants.
    • NCT: 03395210
  • S1820: A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC).
    • Currently enrolling participants.
    • NCT: 04205955

Participate in a Clinic Research Trail

To participate in Clinical Research Trial, please call our office at (989) 631-2469 or email us at